Diabetic Retinopathy and Quality of Life: A Systematic Review and Meta-Analysis.

Gianni Virgili, Ponnusamy Saravanan, Tunde Peto, David Preiss, Mohammed G Zayed, Waseem Karsan

Journal: JAMA ophthalmology 2024;142(3):199-207

PMID: 38300578

Abstract

IMPORTANCE

The association between diabetic retinopathy (DR) and quality of life (QoL) has not been thoroughly investigated.

OBJECTIVE

To investigate the association between DR and both vision-related QoL (VRQoL) and general health-related QoL (HRQoL).

DATA SOURCES

MEDLINE, EBSCO, Embase, and Web of Science were searched from their inception to April 2022.

STUDY SELECTION

Studies included adults with DR and a measure of QoL.

DATA EXTRACTION AND SYNTHESIS

Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines were followed. Two assumption-free meta-analyses were conducted. Analysis 1 included studies with participants without DR as the referent group to which QoL scores of participants with DR, grouped according to DR severity, were compared. Analysis 2 included all studies with participants with DR and a measure of QoL. QoL scores were pooled within categories of DR severity, and comparisons were made between these categories.

MAIN OUTCOME AND MEASURES

QoL measured using HRQoL and VRQoL scales.

RESULTS

A total of 93 articles were included: 79 in the meta-analyses and 14 in the narrative results. VRQoL was recorded in 54 studies, HRQoL in 26, and both in 13 studies. The most commonly used scales were the National Eye Institute 25-item Visual Function Questionnaire (VFQ-25) (n = 49) for VRQoL and the Short Form (SF) Health Survey (n = 18) for HRQoL. Thirty-five studies reported VFQ-25 composite scores. Analysis 1 consisted of 8 studies including 1138 participants with DR and 347 participants without DR. Compared with participants without DR, the composite VFQ-25 score was 3.8 (95% CI, 1.0-6.7) points lower in those with non-vision-threatening DR (NVTDR), 12.5 (95% CI, 8.5-16.5) lower in those with any DR, and 25.1 (95% CI, 22.8-27.2) lower in VTDR (P < .001 for trend). Analysis 2 consisted of 35 studies including 6351 participants with DR. The pooled mean VFQ-25 composite score was 91.8 (95% CI, 91.0-92.7) for participants with NVTDR, 77.6 (95% CI, 76.9-78.3) for any DR, and 73.2 (95% CI, 72.6-73.7) for VTDR (P < .001 for trend). HRQoL scores had weak or no associations with NVTDR and strong associations with VTDR.

CONCLUSIONS AND RELEVANCE

This study found that VRQoL declined with the presence and severity of DR. Interventions to reduce progression of DR at both early and more advanced stages could improve VRQoL.

Address: Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.; Populations, Evidence and Technologies, Division of Health Sciences, Warwick Medical School, University of Warwick, Coventry, United Kingdom.; Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.; Centre for Public Health, Queen's University Belfast, Belfast, United Kingdom.; Department of Ophthalmology, Belfast Health and Social Care Trust, Belfast, United Kingdom.; Populations, Evidence and Technologies, Division of Health Sciences, Warwick Medical School, University of Warwick, Coventry, United Kingdom.; Diabetes, Endocrinology and Metabolism, George Eliot Hospital NHS Trust, Nuneaton, United Kingdom.; AOU Careggi, Department of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA), University of Firenze, Florence, Italy.; Ophthalmology, IRCCS-Fondazione Bietti, Rome, Italy.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.